Compare ARQT & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | CSTM |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | France |
| Employees | N/A | 11500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 2020 | 2012 |
| Metric | ARQT | CSTM |
|---|---|---|
| Price | $24.19 | $29.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $34.00 | $29.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.79 | ★ 405.26 |
| EPS | N/A | ★ 1.92 |
| Revenue | $376,072,000.00 | ★ $8,449,000,000.00 |
| Revenue This Year | $34.46 | $21.45 |
| Revenue Next Year | $29.77 | $0.62 |
| P/E Ratio | ★ N/A | $15.37 |
| Revenue Growth | ★ 91.34 | 15.19 |
| 52 Week Low | $12.42 | $8.09 |
| 52 Week High | $31.77 | $30.14 |
| Indicator | ARQT | CSTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 66.80 |
| Support Level | $22.56 | $13.79 |
| Resistance Level | $25.03 | N/A |
| Average True Range (ATR) | 0.96 | 1.29 |
| MACD | 0.35 | 0.54 |
| Stochastic Oscillator | 77.75 | 93.18 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.